Developing control systems for medical applications poses particular challenges, some of which are unique to this field. Physiological systems involve a multitude of interacting subsystems and networks, with multiple feedforward and feedback loops, and interactions at many levels. The dynamics vary from one individual to another, and within the same individual over time. Many times important states can not be measured, and at times, not even estimated. Quantifying clinical objectives is another challenge, as they do not easily translate into the mathematical performance measures common in control systems theory.
In our current research we are aiming to develop better algorithms to improve insulin dosing in type 1 diabetic individuals. We have two parallel tracks, one aiming at more immediate application with current technology, and a second to have algorithms in place once reliable continuous sensors become available.
Given current constraints of sparse measurements, we are applying a run-to-run strategy to determine the insulin dosing related to meals, as well as for the adjustment of basal infusion rates. This can be incorporated into a continuous control algorithm at a later stage, in which the run-to-run structure can provide feedforward action based on input from the user related to meal consumption.
The long term objective of this work is to develop new algorithmic approaches to optimize the delivery of insulin in an automated fashion to people with type 1 diabetes. Specifically, novel approaches to patient characterization will be developed to predict glucose profiles under various conditions of stress, exploiting developments in pattern recognition from the engineering literature. The net result will be the development of an algorithm that predicts the dosages of insulin delivered to the patient by the clinical team. This will involve the identification of recurring patterns of glucose response to meal and other stimuli. The algorithm will be tested in both simulation and clinical trials for varying degrees of patient stress and meal stimuli, as well as robustness to sensor noise and patient characterization uncertainty.
- Research featured in recent article from the Goleta chamber of commerce
See a recent news article from Goleta Magazine highlighting research from the biomedical control project: Goleta _Magazine_2014 Related Group Members
- Why the First Closed Loop Artificial Pancreas Did Not Come From a Medical School
A recent interview with Scott Hammond, Executive Director of the UCSB Translational Medical Research Laboratories, covers the artificial pancreas project. Read More: http://www.medical-horizons.net/blog-view.php?id=484
- Fully Automated Artificial Pancreas Finally Within Reach
Read a recent press release regarding our work towards the development of an artificial pancreas system. Online: http://jama.jamanetwork.com/article.aspx?articleID=1877064 Related Group Members
- A Pancreas in a Box
The artificial pancreas project was recently highlighted in a Science News Focus, http://dx.doi.org/10.1126/science.343.6167.133 Pancreas_in_a_Box_Science_2014 Image Credit: ROMAN HOVORKA/UNIVERSITY OF CAMBRIDGE METABOLIC RESEARCH LABORATORIES Download Related Lab Members
J. B. Lee, E. Dassau, D. Seborg, F.J. Doyle III, "Model-Based Personalization Scheme of an Artificial Pancreas for Type 1 Diabetes Applications," Proceedings of the American Controls Conference 2013.
E. Dassau, H. Zisser, R.A. Harvey, M.W. Percival, B. Grosman, W. Bevier, E. Atlas, S. Miller, R. Nimri, L. Jovanovic, F.J. Doyle III "Clinical evaluation of a personalized artificial pancreas," Diabetes Care, vol. 36, no. 4, pp. 801-9, Apr 2013. [DOI]
J.J. Lee, E. Dassau, H. Zisser, R.A. Harvey, L. Jovanovič, F.J. Doyle III "In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control," Journal of Diabetes Science and Technology, vol. 7, no. 1, pp. 215-26, January 2013. [PMID]
C. Luni, J.D. Marth, F.J. Doyle III, "Computational modeling of glucose transport in pancreatic β-cells identifies metabolic thresholds and therapeutic targets in diabetes," PloS One, vol. 7, no. 12, pp. e53130, December 2012. [DOI]